Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 May;23(5):948-960.
doi: 10.1007/s12094-020-02539-9. Epub 2021 Mar 2.

SEOM clinical guideline for the management of cutaneous melanoma (2020)

M Majem #  1 , J L Manzano #  2 , I Marquez-Rodas #  3 , K Mujika #  4 , E Muñoz-Couselo #  5 , E Pérez-Ruiz #  6 , L de la Cruz-Merino #  7   8 , E Espinosa #  9 , M Gonzalez-Cao #  10 , A Berrocal #  11
Affiliations
Practice Guideline

SEOM clinical guideline for the management of cutaneous melanoma (2020)

M Majem et al. Clin Transl Oncol. 2021 May.

Abstract

Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish Multidisciplinary Melanoma Group (GEM) has designed these guidelines to homogenize the management of these patients. The diagnosis must be histological and determination of BRAF status has to be performed in patients with stage ≥ III. Stage I-III resectable melanomas will be treated surgically. In patients with stage III melanoma, adjuvant treatment with immunotherapy or targeted therapy is also recommended. Patients with unresectable or metastatic melanoma will receive treatment with immunotherapy or targeted therapy, the optimal sequence of these treatments remains unclear. Brain metastases require a separate consideration, since, in addition to systemic treatment, they may require local treatment. Patients must be followed up closely to receive or change treatment as soon as their previous clinical condition changes, since multiple therapeutic options are available.

Keywords: Adjuvant treatment metastatic treatment; Melanoma; Staging.

PubMed Disclaimer

Conflict of interest statement

MMT reports grants and personal fees from BMS; personal fees from Astra Zeneca, Novartis, Roche, MSD, Boehringer Ingelheim, Takeda, Pierre-Fabre and Bayer; non-financial support from Astra Zeneca, MSD, Boehringer Ingelheim outside the submitted work. JLM reports personal fees from Novartis, Roche, Pierre-Fabre, BMS, MSD and grants from; Merck, Roche, Abbvie, Astra Zeneca outside the submitted work. I.M.-R. has received grants as advisory board member and travel and congress accommodation from BMS, MSD, Roche, Novartis, Amgen, Pierre Fabre, Merck Serono, Sanofi, Regeneron, Incyte, AstraZeneca, and Bioncotech. LCM reports grants and personal fees from BMS, Roche, MSD-Merck, and Amgen, personal fees from Pierre Fabre, Novartis, and grants from Celgene, outside the submitted work. EE reports personal fees from BMS, MSD, Novartis, Pierre Fabre, and Roche. MGC reports personal fees from NOVARTIS, BMS, and Roche. AB reports personal fees and non-financial support from BMS, MSD, Roche, Novartis, Sanofi, and Merck-Pfizer, and personal fees from Pierre Fabre and Incyte, outside the submitted work. KM, EPR, and EMC have nothing to disclose.

Figures

Fig. 1
Fig. 1
Treatment algorithm for primary tumors and regional lymph notes
Fig. 2
Fig. 2
Adjuvant treatment algorithm in high-risk melanoma
See this image and copyright information in PMC

References

    1. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Developing clinical guidelines. West J Med. 1999;170(6):348–351. - PMC - PubMed
    1. Dykewicz CA. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections. Biol Blood Marrow Transpl. 2001;7(Suppl):19S–22S. - PubMed
    1. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics—update 2019. Eur J Cancer (Oxford, England: 1990) 2020;126:141–158. - PubMed
    1. Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161–1171. - PubMed
    1. Gutierrez-Gonzalez E, Lopez-Abente G, Aragones N, Pollan M, Pastor-Barriuso R, Sanchez MJ, et al. Trends in mortality from cutaneous malignant melanoma in Spain (1982–2016): sex-specific age-cohort-period effects. J Eur Acad Dermatol Venereol. 2019;33(8):1522–1528. - PubMed

Publication types

MeSH terms

Substances